Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
Phase 1 of the clinical trial FHD-909 (LY4050784) is progressing according to schedule, with a primary focus on SMARCA4 (BRG1)-mutant cancers, particularly non-small cell lung cancer (NSCLC). The trial involves gradually increasing the dosage to determine the optimal level. This study aims to evaluate the efficacy and safety of the treatment in patients with these specific mutations. The trial is significant for potentially offering a new therapeutic option for patients with SMARCA4 mutations, particularly those with NSCLC.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments